tbuckley/cabot-search huggingface dataset:
Skull base chordoma and spinal chordoma exhibit consistency in terms of endoplasmic reticulum stress aspects
Authors: Hua-Qing Niu, Bo-Yv Zheng, Ming-Xiang Zou, Tao-Lan Zhang, Bo-Wen Zheng
Journal: Neuro-Oncology (2024)

Journal Article Skull base chordoma and spinal chordoma exhibit consistency in terms of endoplasmic reticulum stress aspects Get access Hua-Qing Niu, Hua-Qing Niu Department of Ophthalmology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China Search for other works by this author on: Oxford Academic PubMed Google Scholar Bo-Yv Zheng, Bo-Yv Zheng Department of Orthopedics Surgery, General Hospital of the Central Theater Command, Wuhan, China Search for other works by this author on: Oxford Academic PubMed Google Scholar Ming-Xiang Zou, Ming-Xiang Zou Department of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China https://orcid.org/0000-0002-4516-3917 Search for other works by this author on: Oxford Academic PubMed Google Scholar Tao-Lan Zhang, Tao-Lan Zhang Institute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, ChinaDepartment of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China Search for other works by this author on: Oxford Academic PubMed Google Scholar Bo-Wen Zheng Bo-Wen Zheng Musculoskeletal Tumor Center, Peking University People's Hospital, Peking University, Beijing, China Corresponding author: Bo-Wen Zheng, MD, PhD, Musculoskeletal Tumor Center, Peking University People's Hospital, Peking University, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, China (xcbowen@foxmail.com). Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, noae050, https://doi.org/10.1093/neuonc/noae050 Published: 01 April 2024
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi
Authors: Elliot B. Tapper, Matthew A. Warner, Rajesh P. Shah, Juliet Emamaullee, Nancy M. Dunbar, Michelle Sholzberg, Jacqueline N. Poston, Robin J. Soto, Ammar Sarwar, Anjana Pillai, Karina Reyner, Shivang Mehta, Marwan Ghabril, Timothy R. Morgan, Stephen Caldwell
Journal: Hepatology (2024)

Patients with cirrhosis have abnormal coagulation indices such as a high international normalized ratio and low platelet count, but these do not correlate well with periprocedural bleeding risk. We sought to develop a consensus among the multiple stakeholders in cirrhosis care to inform process measures that can help improve the quality of the periprocedural management of coagulopathy in cirrhosis. We identified candidate process measures for periprocedural coagulopathy management in multiple contexts relating to the performance of paracentesis and upper endoscopy. An 11-member panel with content expertise was convened. It included nominees from professional societies for interventional radiology, transfusion medicine, and anesthesia as well as representatives from hematology, emergency medicine, transplant surgery, and community practice. Each measure was evaluated for agreement using a modified Delphi approach (3 rounds of rating) to define the final set of measures. Out of 286 possible measures, 33 measures made the final set. International normalized ratio testing was not required for diagnostic or therapeutic paracentesis as well as diagnostic endoscopy. Plasma transfusion should be avoided for all paracenteses and diagnostic endoscopy. No consensus was achieved for these items in therapeutic intent or emergent endoscopy. The risks of prophylactic platelet transfusions exceed their benefits for outpatient diagnostic paracentesis and diagnostic endosopies. For the other procedures examined, the risks outweigh benefits when platelet count is >20,000/mm 3 . It is uncertain whether risks outweigh benefits below 20,000/mm 3 in other contexts. No consensus was achieved on whether it was permissible to continue or stop systemic anticoagulation. Continuous aspirin was permissible for each procedure. Clopidogrel was permissible for diagnostic and therapeutic paracentesis and diagnostic endoscopy. We found many areas of consensus that may serve as a foundation for a common set of practice metrics for the periprocedural management of coagulopathy in cirrhosis.
Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in α1-antitrypsin deficiency
Authors: Edgar N. Tafaleng, Jie Li, Yan Wang, Tunda Hidvegi, Alex Soto-Gutierrez, Adam E. Locke, Thomas J. Nicholas, Yung-Chun Wang, Stephen Pak, Michael H. Cho, Edwin K. Silverman, Gary A. Silverman, Sheng Chih Jin, Ira J. Fox, David H. Perlmutter
Journal: Hepatology (2024)

In the classical form of α1-antitrypsin deficiency, a misfolded variant α1-antitrypsin Z accumulates in the endoplasmic reticulum of liver cells and causes liver cell injury by gain-of-function proteotoxicity in a sub-group of affected homozygotes but relatively little is known about putative modifiers. Here, we carried out genomic sequencing in a uniquely affected family with an index case of liver failure and 2 homozygous siblings with minimal or no liver disease. Their sequences were compared to sequences in well-characterized cohorts of homozygotes with or without liver disease, and then candidate sequence variants were tested for changes in the kinetics of α1-antitrypsin variant Z degradation in iPS-derived hepatocyte-like cells derived from the affected siblings themselves.
Neutrophil IL-26 fuels autoinflammation
Authors: Krisztina Futosi, Attila Mócsai
Journal: The Journal of Experimental Medicine (2024)

Pustular psoriasis is an inflammatory skin disease with features of neutrophil-mediated sterile autoinflammation. In this issue of JEM, Baldo et al. (https://doi.org/10.1084/jem.20231464) show that this autoinflammation is driven by a vicious cycle through neutrophil-derived IL-26.
For due or overdue cervical cancer screening, direct or opt-in mailing of HPV self-sampling increased screening at 6 mo vs. education
Authors: Pelin Batur
Journal: Annals of Internal Medicine (2024)

Source CitationWiner RL, Lin J, Anderson ML, et al. Strategies to increase cervical cancer screening with mailed human papillomavirus self-sampling kits: a randomized clinical trial. JAMA. 2023;330:1971-1981. https://pubmed.ncbi.nlm.nih.gov/38015219/
Functional Oxidized Hyaluronic Acid Cross‐Linked Decellularized Heart Valves for Improved Immunomodulation, Anti‐Calcification, and Recellularization
Authors: Yunlong Wu, Xing Chen, Peng Song, Rui Li, Ying Zhou, Qin Wang, Jiawei Shi, Weihua Qiao, Nianguo Dong
Journal: Advanced Healthcare Materials (2024)

Abstract Tissue engineering heart valves (TEHVs) are expected to address the limitations of mechanical and bioprosthetic valves used in clinical practice. Decellularized heart valve (DHV) is an important scaffold of TEHVs due to its natural three‐dimensional structure and bioactive extracellular matrix, but its mechanical properties and hemocompatibility are impaired. In this study, DHV is cross‐linked with three different molecular weights of oxidized hyaluronic acid (OHA) by a Schiff base reaction and presented enhanced stability and hemocompatibility, which could be mediated by the molecular weight of OHA. Notably, DHV cross‐linked with middle‐ and high‐molecular‐weight OHA could drive the macrophage polarization toward the M2 phenotype in vitro. Moreover, DHV cross‐linked with middle‐molecular‐weight OHA scaffolds are further modified with RGD‐PHSRN peptide (RPF‐OHA/DHV) to block the residual aldehyde groups of the unreacted OHA. The results show that RPF‐OHA/DHV not only exhibits anti‐calcification properties, but also facilitates endothelial cell adhesion and proliferation in vitro. Furthermore, RPF‐OHA/DHV shows excellent performance under an in vivo hemodynamic environment with favorable recellularization and immune regulation without calcification. The optimistic results demonstrate that OHA with different molecular weights has different cross‐linking effects on DHV and that RPF‐OHA/DHV scaffold with enhanced immune regulation, anti‐calcification, and recellularization properties for clinical transformation.
In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type
Authors: Jin Ho Hwang, Chi-yuan Hsu
Journal: Annals of Internal Medicine (2024)

Source CitationEMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12:51-60. https://pubmed.ncbi.nlm.nih.gov/38061372/
Management of Inpatient Elevated Blood Pressures
Authors: Linnea M. Wilson, Shoshana J. Herzig, Michael A. Steinman, Mara A. Schonberg, Jennifer L. Cluett, Edward R. Marcantonio, Timothy S. Anderson
Journal: Annals of Internal Medicine (2024)

Management of elevated blood pressure (BP) during hospitalization varies widely, with many hospitalized adults experiencing BPs higher than those recommended for the outpatient setting.
In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y
Authors: Michelle Kelsey, L. Kristin Newby
Journal: Annals of Internal Medicine (2024)

Source CitationRay KK, Nicholls SJ, Li N, et al; CLEAR OUTCOMES Committees and Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12:19-28. https://pubmed.ncbi.nlm.nih.gov/38061370/
In patients with coma due to acute poisoning, withholding intubation improved clinical outcomes
Authors: Evan S. Schwarz
Journal: Annals of Internal Medicine (2024)

Source CitationFreund Y, Viglino D, Cachanado M, et al. Effect of noninvasive airway management of comatose patients with acute poisoning: a randomized clinical trial. JAMA. 2023;330:2267-2274. https://pubmed.ncbi.nlm.nih.gov/38019968/
Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance
Authors: Elias Eythorsson, Saemundur Rognvaldsson, Sigrun Thorsteinsdottir, Thorir Einarsson Long, Elin Ruth Reed, Gudrun Asta Sigurdardottir, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni A. Agnarsson, Margret Sigurdardottir, Isleifur Olafsson, Ingunn Thorsteinsdottir, Signy Vala Sveinsdottir, Fridbjorn Sigurdsson, Asdis Rosa Thordardottir, Runolfur Palsson, Olafur Skuli Indridason, Asbjorn Jonsson, Gauti Kjartan Gislason, Andri Olafsson, Jon Sigurdsson, Hlif Steingrimsdottir, Malin Hultcrantz, Brian G.M. Durie, Stephen Harding, Ola Landgren, Thor Aspelund, Thorvardur Jon Love, Sigurdur Yngvi Kristinsson
Journal: Annals of Internal Medicine (2024)

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions to multiple myeloma and related disorders. Smoldering multiple myeloma is distinguished from MGUS by 10% or greater bone marrow plasma cells (BMPC) on sampling, has a higher risk for progression, and requires specialist management.
Low-dose ketamine safely reduces acute pain in the ED with a more rapid and shorter effect than morphine
Authors: Evan S. Schwarz
Journal: Annals of Internal Medicine (2024)

Source CitationGuo J, Zhao F, Bian J, et al. Low-dose ketamine versus morphine in the treatment of acute pain in the emergency department: a meta-analysis of 15 randomized controlled trials. Am J Emerg Med. 2024;76:140-149. https://pubmed.ncbi.nlm.nih.gov/38071883/
Disparities in Tuberculosis Incidence by Race and Ethnicity Among the U.S.-Born Population in the United States, 2011 to 2021
Authors: Yunfei Li, Mathilda Regan, Nicole A. Swartwood, Terrika Barham, Garrett R. Beeler Asay, Ted Cohen, Andrew N. Hill, C. Robert Horsburgh, Awal Khan, Suzanne M. Marks, Ranell L. Myles, Joshua A. Salomon, Julie L. Self, Nicolas A. Menzies
Journal: Annals of Internal Medicine (2024)

Elevated tuberculosis (TB) incidence rates have recently been reported for racial/ethnic minority populations in the United States. Tracking such disparities is important for assessing progress toward national health equity goals and implementing change.
Association of Albuminuria With Chronic Kidney Disease Progression in Persons With Chronic Kidney Disease and Normoalbuminuria
Authors: Ashish Verma, Insa M. Schmidt, Sophie Claudel, Ragnar Palsson, Sushrut S. Waikar, Anand Srivastava
Journal: Annals of Internal Medicine (2024)

Albuminuria is a major risk factor for chronic kidney disease (CKD) progression, especially when categorized as moderate (30 to 300 mg/g) or severe (>300 mg/g). However, there are limited data on the prognostic value of albuminuria within the normoalbuminuric range (<30 mg/g) in persons with CKD.
3D Navigation and Intraprocedural Intracardiac Echocardiography Imaging for Tricuspid Transcatheter Edge-to-Edge Repair
Authors: Nadira Hamid, Edris Aman, Richard Bae, Markus Scherer, Thomas W.R. Smith, Jonathan Schwartz, Michael Rinaldi, Gagan Singh, Paul Sorajja
Journal: JACC. Cardiovascular imaging (2024)
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
Authors: Zachary L. Cox, Sean P. Collins, Gabriel A. Hernandez, A. Thomas McRae, Beth T. Davidson, Kirkwood Adams, Mark Aaron, Luke Cunningham, Cathy A. Jenkins, Christopher J. Lindsell, Frank E. Harrell, Christina Kampe, Karen F. Miller, William B. Stubblefield, JoAnn Lindenfeld
Journal: Journal of the American College of Cardiology (2024)
Cancer-derived exosomes as novel biomarkers in metastatic gastrointestinal cancer
Authors: Danyang Zhong, Ziyuan Wang, Zhichao Ye, Yifan Wang, Xiujun Cai
Journal: Molecular Cancer (2024)

Abstract Gastrointestinal cancer (GIC) is the most prevalent and highly metastatic malignant tumor and has a significant impact on mortality rates. Nevertheless, the swift advancement of contemporary technology has not seamlessly aligned with the evolution of detection methodologies, resulting in a deficit of innovative and efficient clinical assays for GIC. Given that exosomes are preferentially released by a myriad of cellular entities, predominantly originating from neoplastic cells, this confers exosomes with a composition enriched in cancer-specific constituents. Furthermore, exosomes exhibit ubiquitous presence across diverse biological fluids, endowing them with the inherent advantages of non-invasiveness, real-time monitoring, and tumor specificity. The unparalleled advantages inherent in exosomes render them as an ideal liquid biopsy biomarker for early diagnosis, prognosticating the potential development of GIC metastasis. In this review, we summarized the latest research progress and possible potential targets on cancer-derived exosomes (CDEs) in GIC with an emphasis on the mechanisms of exosome promoting cancer metastasis, highlighting the potential roles of CDEs as the biomarker and treatment in metastatic GIC.
Engineered extracellular vesicle-based gene therapy for the treatment of discogenic back pain
Authors: Shirley N. Tang, Ana I. Salazar-Puerta, Mary K. Heimann, Kyle Kuchynsky, María A. Rincon-Benavides, Mia Kordowski, Gilian Gunsch, Lucy Bodine, Khady Diop, Connor Gantt, Safdar Khan, Anna Bratasz, Olga Kokiko-Cochran, Julie Fitzgerald, Damien M. Laudier, Judith A. Hoyland, Benjamin A. Walter, Natalia Higuita-Castro, Devina Purmessur
Journal: Biomaterials (2024)

Painful musculoskeletal disorders such as intervertebral disc (IVD) degeneration associated with chronic low back pain (termed "Discogenic back pain", DBP), are a significant socio-economic burden worldwide and contribute to the growing opioid crisis. Yet there are very few if any successful interventions that can restore the tissue's structure and function while also addressing the symptomatic pain. Here we have developed a novel non-viral gene therapy, using engineered extracellular vesicles (eEVs) to deliver the developmental transcription factor FOXF1 to the degenerated IVD in an in vivo model. Injured IVDs treated with eEVs loaded with FOXF1 demonstrated robust sex-specific reductions in pain behaviors compared to control groups. Furthermore, significant restoration of IVD structure and function in animals treated with FOXF1 eEVs were observed, with significant increases in disc height, tissue hydration, proteoglycan content, and mechanical properties. This is the first study to successfully restore tissue function while modulating pain behaviors in an animal model of DBP using eEV-based non-viral delivery of transcription factor genes. Such a strategy can be readily translated to other painful musculoskeletal disorders.
The senescence journey in cancer immunoediting
Authors: Alessandra Zingoni, Fabrizio Antonangeli, Silvano Sozzani, Angela Santoni, Marco Cippitelli, Alessandra Soriani
Journal: Molecular Cancer (2024)

Abstract Cancer progression is continuously controlled by the immune system which can identify and destroy nascent tumor cells or inhibit metastatic spreading. However, the immune system and its deregulated activity in the tumor microenvironment can also promote tumor progression favoring the outgrowth of cancers capable of escaping immune control, in a process termed cancer immunoediting. This process, which has been classified into three phases, i.e. “elimination”, “equilibrium” and “escape”, is influenced by several cancer- and microenvironment-dependent factors. Senescence is a cellular program primed by cells in response to different pathophysiological stimuli, which is based on long-lasting cell cycle arrest and the secretion of numerous bioactive and inflammatory molecules. Because of this, cellular senescence is a potent immunomodulatory factor promptly recruiting immune cells and actively promoting tissue remodeling. In the context of cancer, these functions can lead to both cancer immunosurveillance and immunosuppression. In this review, the authors will discuss the role of senescence in cancer immunoediting, highlighting its context- and timing-dependent effects on the different three phases, describing how senescent cells promote immune cell recruitment for cancer cell elimination or sustain tumor microenvironment inflammation for immune escape. A potential contribution of senescent cells in cancer dormancy, as a mechanism of therapy resistance and cancer relapse, will be discussed with the final objective to unravel the immunotherapeutic implications of senescence modulation in cancer.
Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial
Authors: Naveed Sattar, Javed Butler, Matthew M.Y. Lee, Josephine Harrington, Abhinav Sharma, Faiez Zannad, Gerasimos Filippatos, Subodh Verma, James L. Januzzi, João Pedro Ferreira, Stuart J. Pocock, Egon Pfarr, Anne P. Ofstad, Martina Brueckmann, Milton Packer, Stefan D. Anker
Journal: European Journal of Heart Failure (2024)

Both low and high body mass index (BMI) are associated with poor heart failure outcomes. Whether BMI modifies benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in heart failure with preserved ejection fraction (HFpEF) requires further investigation. Using EMPEROR-Preserved data, the effects of empagliflozin versus placebo on the risks for the primary outcome (hospitalization for heart failure [HHF] or cardiovascular [CV] death), change in estimated glomerular filtration rate (eGFR) slopes, change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), and secondary outcomes across baseline BMI categories (<25 kg/m2, 25 to <30 kg/m2, 30 to <35 kg/m2, 35 to <40 kg/m2 and ≥40 kg/m2) were examined, and a meta-analysis conducted with DELIVER. Forty-five percent had a BMI of ≥30 kg/m2. For the primary outcome, there was a consistent treatment effect of empagliflozin versus placebo across the BMI categories with no formal interaction (p trend = 0.19) by BMI categories. There was also no difference in the effects on secondary outcomes including total HHF (p trend = 0.19), CV death (p trend = 0.20), or eGFR slope with slower declines with empagliflozin regardless of BMI (range 1.12-1.71 ml/min/1.73 m2 relative to placebo, p trend = 0.85 for interaction), though there was no overall impact on the composite renal endpoint. The difference in weight change between empagliflozin and placebo was -0.59, -1.48, -1.54, -0.87, and - 2.67 kg in the lowest to highest BMI categories (p trend = 0.016 for interaction). A meta-analysis of data from EMPEROR-Preserved and DELIVER showed a consistent effect of SGLT2i versus placebo across BMI categories for the outcome of HHF or CV death. There was a trend toward greater absolute KCCQ-CSS benefit at 32 weeks with empagliflozin at higher BMIs (p = 0.08). Empagliflozin treatment resulted in broadly consistent cardiac effects across the range of BMI in patients with HFpEF. SGLT2i treatment yields benefit in patients with HFpEF regardless of baseline BMI.
Cost‐effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS‐HF system) in chronic heart failure in the Netherlands
Authors: Hamraz Mokri, Pascal R.D. Clephas, Rudolf A. de Boer, Pieter van Baal, Jasper J. Brugts, Maureen P.M.H. Rutten‐van Mölken
Journal: European Journal of Heart Failure (2024)

Remote haemodynamic monitoring with an implantable pulmonary artery (PA) sensor has been shown to reduce heart failure (HF) hospitalizations and improve quality of life. Cost-effectiveness analyses studying the value of remote haemodynamic monitoring in a European healthcare system with a contemporary standard care group are lacking.
Maternal circadian rhythm disruption affects neonatal inflammation via metabolic reprograming of myeloid cells
Authors: Zhaohai Cui, Haixu Xu, Fan Wu, Jiale Chen, Lin Zhu, Zhuxia Shen, Xianfu Yi, Jinhao Yang, Chunhong Jia, Lijuan Zhang, Pan Zhou, Mulin Jun Li, Lu Zhu, Shengzhong Duan, Zhi Yao, Ying Yu, Qiang Liu, Jie Zhou
Journal: Nature Metabolism (2024)
Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression
Authors: Olivia Sirpilla, R. Leo Sakemura, Mehrdad Hefazi, Truc N. Huynh, Ismail Can, James H. Girsch, Erin E. Tapper, Michelle J. Cox, Kendall J. Schick, Claudia Manriquez-Roman, Kun Yun, Carli M. Stewart, Ekene J. Ogbodo, Brooke L. Kimball, Long K. Mai, Omar L. Gutierrez-Ruiz, Makena L. Rodriguez, Martina Gluscevic, Daniel P. Larson, Alex M. Abel, Wesley A. Wierson, Gloria Olivier, Elizabeth L. Siegler, Saad S. Kenderian
Journal: Nature Biomedical Engineering (2024)
CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation
Authors: Junxiong Chen, Yingjun Ding, Chao Jiang, Rongmei Qu, Jonathan D. Wren, Constantin Georgescu, Xuejun Wang, Darlene N. Reuter, Beibei Liu, Cory B. Giles, Christoph H. Mayr, Herbert B. Schiller, Jingxing Dai, Christopher S. Stipp, Bharathiraja Subramaniyan, Jie Wang, Houjuan Zuo, Chao Huang, Kar-Ming Fung, Heather C. Rice, Arnoud Sonnenberg, David Wu, Matthew S. Walters, You-Yang Zhao, Tomoharu Kanie, Franklin A. Hays, James F. Papin, Dao Wen Wang, Xin A. Zhang
Journal: Circulation Research (2024)

Tetraspanin CD151 is highly expressed in endothelia and reinforces cell adhesion, but its role in vascular inflammation remains largely unknown.
Role of PD‐L1 in Arthritis: Comment on the Article by Wood et al
Authors: Wang‐Dong Xu, An‐Fang Huang
Journal: Arthritis & Rheumatology (2024)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.